DVA

Business profile & competitive position

DaVita Inc. (DVA) sits in the Healthcare sector, specifically the Medical - Care Facilities industry. Its core business is kidney care, delivered through outpatient dialysis centers, hospital-based dialysis services, and related integrated care models. Revenue is recurring and reimbursement-driven, tied to the volume of treatments performed rather than to discretionary consumer demand or one-time product cycles.

The financial profile shows both a profit and a capital-structure warning. The 6.0% net margin confirms the company can convert treatment revenue into bottom-line earnings, but it also reflects the low-margin, capital- and labor-intensive nature of running care facilities. The trailing ROE of -123.6% is the more unusual figure. Because net margin is positive, a deeply negative ROE usually signals a negative or very small shareholders’ equity base—often the product of leverage, accumulated deficits, or aggressive share repurchases. That means ROE cannot be read as a clean “competitive moat” signal here; the balance sheet has to be evaluated alongside operating profitability.

Financial posture

DaVita currently carries an $11.7 billion market capitalization and trades at a P/E ratio of 15.6, a multiple that sits below many higher-growth healthcare services names. The stock was at $181.78 as of the latest snapshot, with a beta of 0.87, implying the shares have historically moved a bit less than the overall market.

The short-term snapshot shows technical stress: the RSI is 23.6, a level technicians often describe as deeply oversold, while the price sits roughly 15% below the 50-day EMA of $213.52. Against that backdrop, the 6.0% net margin and -123.6% ROE give the 15.6 P/E a mixed interpretation. The valuation is not expensive relative to earnings, but the negative equity position and compressed margin suggest the market is pricing in reimbursement or cost pressures rather than awarding a scarcity premium.

Macro & geopolitical exposure

As a Medical - Care Facilities company, DaVita is mainly exposed to the structural forces that shape the U.S. healthcare system rather than to commodity prices or direct consumer spending cycles. The most important macro variable is reimbursement policy: dialysis providers depend heavily on Medicare, Medicaid, and commercial insurer rates, so changes to CMS payment schedules, bundled-payment frameworks for end-stage renal disease, or value-based kidney-care models can directly affect revenue per treatment.

The industry is also rate- and labor-sensitive. Higher interest rates raise the carrying cost of facility leases and any floating-rate obligations, while clinical-staff wage inflation compresses margins. Trade policy is generally less central than in manufacturing, but tariffs on imported dialysis equipment, pharmaceuticals, or consumables could still pass through as higher supply-chain costs. Currency exposure is comparatively limited for U.S.-focused care-facility operators. In short, regulatory and reimbursement risk outweighs geopolitical headline risk for this classification.

Recent developments

The latest headlines illustrate the gap between reported earnings and investor reaction. On August 4, 2026, DaVita reported Q2 EPS of $4.02 versus a $3.88 consensus estimate, a 3.6% beat. Yet two Zacks.com stories dated August 5, 2026 noted that the stock fell in pre-market trading and then dropped 17.24% the next session, with one headline citing margin pressure and another saying the Q2 earnings call centered on clinical-led volume growth.

That same day, August 5, 2026, Schaeffersresearch.com reported that the Dow Jones Industrial Average extended its record run with a more than 400-point gain, making DaVita’s post-earnings decline stand out against a broadly advancing market. On August 6, 2026, Zacks.com asked whether DVA is a value stock right now, a framing that links directly to the lower P/E and the sharp pullback following a beat.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, DaVita has beaten earnings estimates six times, a 75% beat rate, with an average earnings surprise of 2.3%. The average five-day post-earnings move across those quarters is 15.74% to the upside, and the drift direction is classified as “up.” That average, however, hides very wide single-report outcomes.

The last four quarters make the dispersion clear. The May 5, 2026 report delivered a 19.1% EPS surprise—actual $2.87 versus estimate $2.41—and the stock surged 23.46% the next day and 27.7% over the next five sessions. The February 2, 2026 quarter produced a 4.9% beat ($3.40 vs. $3.24) with a 21.17% next-day jump and a 23.79% five-day drift. By contrast, the October 29, 2025 quarter was a -20.8% miss ($2.51 vs. $3.17) that led to a -6.17% next-day drop and a -4.27% five-day drift. Most recently, the August 4, 2026 beat produced a -17.24% one-day reversal and a 0% five-day follow-through, showing that a beat does not guarantee a rally.

DaVita is next scheduled to report on October 28, 2026 after the close, with the current consensus EPS estimate at $3.78. The historical record shows positive surprises have been more common than negative surprises, but the post-announcement price path has been binary, so beat-or-miss is only one input into how the stock may trade.

For a deeper dive into how sell-side models, institutional ownership, and management guidance interact with these numbers, explore the full institutional verdict on DaVita. It provides the broader context behind the headline figures and helps frame the next earnings catalyst without substituting one-size-fits-all advice.